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Synopsis 
The glycoprotein hormones, Luteinizing Hormone (LH), human Chorionic Gonadotropin (hCG), 
Follicle Stimulating Hormone (FSH) and Thyroid Stimulating Hormone (TSH) are heterodimeric 
proteins with an identical α-subunit associated non-covalently with the hormone specific β-subunit 
and play important roles in reproduction and overall physiology of the organism [1]. The receptors of 
these hormones belong to the family of G-protein coupled receptors (GPCR) and have a large 
extracellular domain (ECD) comprising of 9-10 leucine rich repeats (LRR) followed by a flexible 
hinge region, a seven helical transmembrane domain (TMD) and a C terminal cytoplasmic tail [2]. 
Despite significant sequence and structural homologies observed between the ECDs of the receptors 
and the specific β-subunits of the hormones, the hormone-receptor pairs exhibit exquisite specificity 
with very low cross-reactivity with other members of the family.  The TSH receptor (TSHR) is an 
especially interesting member of this family as it not only recognizes is cognate ligand, i.e. TSH, but 
also binds to the non-cognate ligands such as autoantibodies.  TSHR autoantibodies come in 
different flavors; inhibitory antibodies that compete with the hormone for receptor binding and block 
its action, stimulatory antibodies that activate the receptor in a hormone independent manner and 
neutral antibodies that bind to the receptor but do not directly influence its functions. The inhibitory 
autoantibodies cause hypothyroidism and are responsible for Hashimoto’s Thyroiditis, whereas the 
stimulatory  autoantibodies cause Graves’ thyrotoxicosis characterized by hyperthyroid condition [3]. 
The exact epitopes of these autoantibodies are not well delineated although it has been hypothesized 
that the blocking type- and the stimulatory type- autoantibodies have predominant epitopes in the 
TSHR ECD that overlap with hormone binding regions [4]. Insights into the mode of hormone or 
autoantibody binding to the receptor was primarily derived from the  crystal structure of FSHR 
leucine rich repeat domain (LRRD) bound to single chain analog of FSH, and the crystal structures of 
TSHR LRRD bound to the stimulatory type human monoclonal antibody M22 [5] and the inhibitory 
type- monoclonal antibody K1-70 [6].  Both these crystal structures propose LRRDs as the primary 
ligand binding site which  interacts with the hormone through its determinant loop in a hand-clasp 
fashion [7] while the autoantibodies mimics the hormone binding to a large extent [8] . These 
structures, while providing detailed understanding of the molecular interactions of the LRRs with the 
hormone, shed little light on the mechanism by which the signal generated at the LRRD are 
transduced to the downstream effector regions at the distally situated TMD. Hence, while one 
understands the ligand binding to a large extent, the activation process is not well understood, one of 
the central objective of the present study. 
Ligand-receptor interactions are typically studied by perturbing ligand/receptor structure by 
mutagenesis or by mapping conformational changes by biophysical or computational approaches. In 
addition to the above-mentioned approaches, the present work also uses highly specific antibodies 
against different domains of the receptor as molecular probes due to the ability of antibodies to 
distinguish between conformations likely to arise during the activation process. Use of antibodies to 
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understand the receptor activation process is especially apt for TSHR due to the presence of 
physiologically relevant TSHR autoantibodies and their ability to influence hormone binding and 
receptor activation [9, 10]. Chapter 2 attempts to provide a comparison between the interactions of 
the hormone and the autoantibodies with TSHR. For this purpose, two assays were developed for 
identification of TSHR autoantibodies in the sera of patients suffering from autoimmune thyroid 
diseases (AITD), the first assay is based on the ability of TSHR autoantibodies to compete for 
radiolabeled hormone (The TSH binding inhibition (TBI), assay) and the second based on the 
capability of stimulatory antibody to produce cAMP in cells expressing TSHR (TSHR stimulatory 
immunoglobin (TSI) assay). A stable cell line expressing TSHR capable of recognizing both TSH and 
TSHR autoantibodies was thus created and used for prospective and retrospective analysis of AITD 
patients. Based on the TBI and TSI profiles of IgGs,  purified from AITD patient's sera, it was 
recognized that TSHR stimulatory and TSH binding inhibitory effects of these antibodies correlated 
well, indicating overlap between hormone binding and IgG binding epitopes. It was also recognized 
that stimulatory IgGs are not affected by negative regulatory mechanism that governs TSH secretion 
substantiating the persistence of these antibodies in circulation. Kinetics of cAMP production by 
Graves’ stimulatory IgG was found to be fundamentally distinct, where the autoantibodies displayed 
pronounce hysteresis during the onset of the activation process when compared to the hormone. 
This could possibly be explained by the oligoclonality of the autoantibody population, a different 
mechanism of receptor activation or dissimilarity in autoantibody and hormone epitopes. To gain 
additional insights into the epitopes of TSHR autoantibodies and the regions that might be critical in 
the activation process, different overlapping fragments encompassing the entire TSH receptor ECD 
were cloned, expressed in E.coli as GST fusion proteins and purified:  1] the first three LRRs (TLRR 
1-3, amino acid (aa) 21-127), 2] the first six LRRs (TLRR 1-6, aa 21-200), 3] the putative major 
hormone binding domain (TLRR 4-6, aa 128-200), and 4] the hinge region of TSH receptor along 
with LRR 7 to 9, (TLRR 7-HinR, aa 201-413). The receptor fragment TLRR 7-HinR was further 
subdivided into LRR 7-9 (TLRR 7-9, aa 201-161) and the hinge region (TSHR HinR, aa 261-413), 
expressed as N-terminal His-Tagged protein and purified using IMAC chromatography. 
Simultaneously, the full-length TSHR ECD was cloned, expressed and purified using the Pichia pastoris 
expression system. ELISA or immunoblot analysis of autoantibodies with the TSHR exodomain 
fragments suggested that Graves’ stimulatory antibody epitopes were distributed throughout the 
ECD with LRR 4-9 being the predominant site of binding. Interestingly, experiments involving 
neutralization of Graves’ IgG stimulated cAMP response by different receptor fragment indicated 
that fragments corresponding to the TSHR hinge region were better inhibitors of autoantibody 
stimulated receptor response than corresponding LRR fragments, suggesting that the hinge region 
might be an important component of the receptor activation process. 
This was in contrast to prevalent beliefs that considered the hinge region to be an inert linker 
connecting the LRRs to the TMD, a structural entity without any known functional significance. 
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Mutagenesis in TSHR hinge region and agonistic antibodies against FSHR and LHR hinge regions, 
reported by the laboratory, recognized the importance of the hinge regions as critical for receptor 
activation and may not simply be a scaffold [11-13].  Unfortunately, the mechanism by which the 
hinge region regulates binding or response or both have not been well understood partially due to 
unavailability of structural information about this region. In addition poor sequence similarity within 
the GpHR family and within proteins of known structure, make this region difficult to model 
structurally. In chapter 3, effort is made to model the hinge regions of the three GpHR based on the 
knowledge driven and Ab initio protocols. An assembled structure comprising of the LRR domain 
(derived from the known structures of FSHR and TSHR LRR domains) and the modeled hinge 
region and transmembrane domain presents interesting differences between the three receptors, 
especially in the manner the hormone bound LRRD is oriented towards the TMD. These models also 
suggested that the α-subunit interactions in these three receptors are fundamentally different and this 
was verified by investigating the effects of two α-subunit specific MAbs C10/2A6 on hCG-LHR and 
hTSH-TSHR interactions. These two α-subunit MAbs had inverse effects on binding of hormone to 
the receptor. MAb C10 inhibited TSH binding to TSHR but not that of hCG, whereas MAb 2A6 
inhibited binding of hCG to LHR but not of hTSH. Investigation into the accessibility of their 
epitopes in a preformed hormone receptor complex indicated that the α-subunit may become buried 
or undergo conformational change during the activation process and interaction may be different for 
LHR and TSHR. 
Fundamental differences in TSHR and LHR were further investigated in the next chapter (Chapter 
4), especially with regards to the ligand independent receptor activation. Polyclonal antibodies were 
developed against LRR 1-6, TLRR 7-HinR and the TSHR HinR receptor fragments. The LRR 1-6 
antibodies were potent inhibitor of receptor binding as well as response, similar to that observed with 
antibodies against the corresponding regions of LHR. Interestingly, the antibodies against the hinge 
region of TSHR were unable to inhibit hTSH binding, but were effective inhibitors of cAMP 
production suggesting that this region may be involved in a later stage of a multi-step activation 
process. This was also verified by studying the mechanism of inhibition of receptor response and 
their effect on ligand-receptor association and dissociation kinetics. Hinge region-specific antibodies 
immunopurified from TLRR 7-HinR antibodies behaved akin to those of the pure hinge region 
antibodies providing independent validation of the above results. This result was, however, in 
contrast to those observed with a similar antibody against LHR hinge region. As compared to the 
TSHR antibody, the LHR antibody inhibited both hormone binding and response. In addition, this 
antibody could dissociate a preformed hormone-receptor complex which was not observed for 
TSHR hinge region antibodies. Although unable to dissociate preformed hormone-receptor complex 
by itself, the TSHR HinR antibodies augmented hormone induced dissociation of the hormone-
receptor complex suggesting that this region may be involved in modulation of negative cooperativity 
associated with TSHR.   
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Molecular dissection of the role of hinge region of TSHR was further carried out by using 
monoclonal antibodies against LRR 1-3 (MAb 413.1.F7), LRR 7-9 (MAb 311.87), TSHR hinge region 
(MAb 311.62 and MAb PD1.37). MAb 311.62 which identifies the LRR/Cb-2 junction (aa 265-275), 
increased the affinity of TSHR for the hormone while concomitantly decreasing its efficacy, whereas 
MAb 311.87 recognizing LRR 7-9 (aa 201-259) acted as a non-competitive inhibitor of TSH binding. 
MAb 413.1.F7 did not affect hormone binding or response and was used as the control antibody for 
different experiments. Binding of MAbs was sensitive to the conformational changes caused by the 
activating and inactivating mutations and exhibited differential effects on hormone binding and 
response of these mutants.  By studying the effects of these MAbs on truncation and chimeric 
mutants of thyroid stimulating hormone receptor (TSHR), this study confirms the tethered inverse 
agonistic role played by the hinge region and maps the interactions between TSHR hinge region [14] 
and exoloops responsible for maintenance of the receptor in its basal state. Mechanistic studies on 
the antibody-receptor interactions suggest that MAb 311.87 is an allosteric insurmountable antagonist 
and inhibits initiation of the hormone induced conformational changes in the hinge region, whereas 
MAb 311.62 acts as a partial agonist that recognizes a conformational epitope critical for coupling of 
hormone binding to receptor activation. Estimation of apparent affinities of the antibody to the 
receptor and the cooperativity factor suggests that epitope of MAb 311.87 (LRR 7-9) may act as a 
pivot involved in the initial events immediate to hormone binding at the LRRs. The anatgonsitic 
effect of MAB 311.62 on binding and response also suggested that binding of hormone is 
conformationally selective rather than an induced event. The hinge region, probably in close 
proximity with the α-subunit in the hormone-receptor complex, acts as a tunable switch between 
hormone binding and receptor activation. 
In contrast to the stimulatory nature of  Cb-2 antibody such as MAb 311.62, MAb PD1.37, which 
identified residues aa 366–384 near Cb-3, was found to be inverse agonistic. Unlike other known 
inverse agonistic MAbs such as CS-17 [15] and 5C9 [16], MAb PD1.37 did not compete for TSH 
binding to TSHR, although it could  inhibit hormone stimulated response. Moreover, unlike CS-17, 
MAb PD1.37 was able to decrease elevated basal cAMP of hinge region constitutively activated 
mutations only but not those in the extracellular loops. This is particularly important as interaction of 
hinge region residues with those of ECLs had been thought to be critical in maintenance of the basal 
level of receptor activation and are responsible for attenuating the constitutive basal activity of the 
mutant and wild-type receptors in the absence of the hormone. This was demonstrated by a marked 
increase in the basal constitutive activity of the receptor upon the complete removal of its 
extracellular domain, which returned to the wild-type levels upon reintroduction of the hinge region. 
However, careful comparison of the activities of the mutants (receptors harboring deletions and gain-
of-function mutations) with maximally stimulated wild-type TSHR indicated that these mutations of 
the receptor resulted primarily in partial activation of the serpentine domain suggesting that only the 
ECD in complex with the hormone is the full agonist of the receptor.   
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Confirmation of the above proposition has been difficult to verify primarily due to a highly transient 
conformational change in the tripartite interaction of the hinge region/hormone and the ECLs. The 
current approaches of using antibodies to probe the ECLs are difficult due to the conformational 
nature of the antigen as well as difficulty in obtaining a soluble protein. In chapter 5, the ligand 
induced conformational alterations in the hinge regions and inter-helical loops of 
LHR/FSHR/TSHR were mapped using the exoloop specific antibodies generated against a mini-
Transmembrane domain (mini-TMD) protein. This mini-TMD protein, designed to mimic the native 
exoloop conformations, was created by joining the TSHR exoloops, constrained through the helical 
tethers and library derived linkers. The antibody against mini-TMD specifically recognized all three 
GpHRs and inhibited the basal and hormone stimulated cAMP production without affecting 
hormone binding. Interestingly, binding of the antibody to all three receptors was abolished by prior 
incubation of the receptors with the respective hormones suggesting that the exoloops are buried in 
the hormone-receptor complexes. The antibody also suppressed the high basal activities of gain-of-
function mutations in the hinge regions, exoloops and TMDs such as those involved precocious 
puberty and thyroid toxic adenomas. Using the antibody and point/deletion/chimeric receptor 
mutants, dynamic changes in hinge region-exoloop interactions were mapped.  The computational 
analysis suggests that mini-TMD antibodies act by conformationally locking the transmembrane 
helices by restraining the exoloops and juxta-membrane regions. This computational approach of 
generating synthetic TMDs bears promise in development of interesting antibodies with therapeutic 
potential, as well as, explains the role of exoloops during receptor activation. 
In conclusion (Chapter 6), the study provides a comprehensive outlook on the highly dynamic 
interaction of ligand and different subdomains of the TSHR (and to a certain extent of LHR and 
FSHR) and proposes a model of receptor activation where the receptor is in a dynamic equilibrium 
between the low affinities constrained state and the high affinity unconstrained state and bind to the 
hormone through the LRR 4-6.  Upon binding the βL2 loop of the hormone contact LRR 8-10 that 
triggers a conformational change in the hinge region driving the α-subunit to contact the ECLs. Upon 
contact, the ECLs cooperatively causes helix movement in the TMH and ultimately in ICLs causing 
the inbuilt GTP-exchange function of a GPCR. 
 
 
 
 
 
 
 
